<DOC>
	<DOCNO>NCT02559648</DOCNO>
	<brief_summary>This single-site , randomize , placebo-controlled , double blind phase 2b clinical trial . Patients Thalassemia participate study treat Denosumab placebo . The effect Denosumab lumbar spine BMD patient Thalassemia Major Osteoporosis evaluate compare control ( placebo ) 12 month .</brief_summary>
	<brief_title>Denosumab v Placebo Patients With Thalassemia Major Osteoporosis</brief_title>
	<detailed_description>This single-site , randomize , placebo-controlled , double blind phase 2b clinical trial . Patients Thalassemia Bone Mass Density ( BMD ) T-score -2.5 - 4.0 least one examine site participate study treat Denosumab placebo . Patients assign two ( 2 ) treatment group : - In Group A , 60 mg Denosumab administer sc , every 6 month 12 month total 2 dos ( day 0 day 180 ) . - In Group B placebo administer sc , every 6 month 12 month total 2 dos ( day 0 day 180 ) ( Appendix I Appendix II ) . Patients randomly assign , 1:1 fashion , two therapeutic arm ( Group A , Group B , respectively ) , upon enrollment study . The effect Denosumab lumbar spine BMD ( bone mineral density ) patient Thalassemia Major Osteoporosis compare control 12 month evaluate . Also effect femoral neck wrist bone BMD , marker bone remodel safety profile evaluate well . All subject receive subcutaneous injection Denosumab placebo administer health care professional day 0 180 ( ±3 ) .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Adults ( &gt; 30 year age ) describe skeletally mature subject Thalassemia Major Low BMD ( Tscore &lt; 2.5 ) one 3 study site ( lumbar spine , femoral neck , wrist ) . Have sign inform consent form ( consent take studyspecific procedure perform ) . BMD Tscore &lt; 4.0 one 2 study site ( lumbar spine , femoral neck ) . Previous administration denosumab clinical trial others ( e.g . commercial use ) . Current participation another clinical trial receive investigational product within last 3 month . Impaired renal function determine estimate glomerular filtration rate ( eGFR ) ≤ 30 mL/min ( use Chronic Kidney DiseaseEpidemiology , ( ( CKDEPI ) formula ) . Patients sickle cell disease . Known liver failure chronic hepatic disease e.g . cirrhosis , chronic hepatitis ; elevate transaminase define Alanine Transaminase ( ALT ) and/or Aspartate Transaminase ( AST ) &gt; 2 fold upper limit normal laboratory range . Heart failure ( NYHA 2 ) . Patients life expectancy le one year . Subject refuse use reliable contraceptive method ( oral contraceptive , progesterone implant , intrauterine device , condom ) throughout study woman childbearing potential . Women childbearing potential agree use 2 highly effective form contraception continue practice 7 month last injection study medication . Pregnancy , plan pregnancy currently lactate Severe concurrent illness investigator 's opinion may confound patient evaluation , e.g . malignancy ( except basal cell carcinoma , cervical breast ductal carcinoma situ ) within last 5 year . Known alcohol drug abuse condition associate poor compliance Patients receive oral bisphosphonates within 6 month study enrollment intravenous bisphosphonates , fluoride strontium ranelate within 1 year study enrollment . Parathormone ( PTH ) , PTH derivative , teriparatide , odanacatib , anabolic steroid , testosterone , glucocorticosteroids ( &gt; 5 mg/day prednisone equivalent &gt; 10 day ) , systemic hormonereplacement therapy , selective estrogen receptor modulators ( SERMs ) , raloxifene , tibolone , calcitonin calcitriol use within last 6 week . Evidence hyper hypothyroidism ; patient abnormal Thyroid stimulate hormone ( TSH ) level thyroid treatment ( patient stable thyroid treatment normal TSH allow ) ; current hyper hypoparathyroidism ; current hyper hypocalcemia ( hypocalcemia base albumin adjust serum calcium &lt; 8.5 mg/dL ) ; vitamin D deficiency ( 25hydroxy Vitamin D level &lt; 12 ng/mL ; repeat 1220 ng/mL repletion , subject allow ) ; rheumatoid arthritis ; Paget 's disease ; bone disease would interfere interpretation finding . Known sensitivity mammalian cellderived drug product . History Solid Organ Bone Marrow Transplant History osteonecrosis jaw , and/or recent tooth extraction dental surgery ; plan invasive dental work study . Intolerance calcium supplement . Malabsorption syndrome ; severe malabsorption include Celiac disease , Short Bowel Syndrome , Crohn 's disease , Previous Gastric Bypass .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>